By Matthew Makowski Even the best penny stocks come with risk. There are lots of biopharmaceutical outfits with promising product pipelines. But they don’t always make it to the shelf in time… Leading to bankruptcy or cheap acquisitions for the competition. And that’s bad news for investors.
A new tech startup trading over-the-counter (OTC) can get purchased by the competition before it has the chance to make it to a larger index… Leaving investors wondering “what if.” Or, as 2008 proved, even major players in the banking industry aren’t too big to do lasting damage to investors’ portfolios.
Nonetheless, penny stocks have a special draw …read more
